Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Brodalumab: Phase II data

A double-blind, U.S. and Canadian Phase II trial in 159 evaluable adults with psoriatic arthritis showed that 140 and 280 mg subcutaneous brodalumab given once every 2 weeks each met the primary endpoint

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers